Quanterix Corp. has announced a collaboration with Eli Lilly and Co. to advance the diagnosis, monitoring and treatment of Alzheimer’s disease, according to a press release.
Via the collaboration, Quanterix will receive a nonexclusive, worldwide license to Lilly’s proprietary P-tau217 antibody technology, which may aid in near-term use in research-only products and services and future in vitro diagnostic applications. The collaborators also agreed on a framework for future projects centered around the development of Simoa immunoassays.
Under the agreement, Lilly will fund $11